CURASIGHT A/S |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.1 DKK | -8.82% |
|
-9.45% | -48.73% |
| Apr. 16 | Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients | CI |
| Apr. 12 | Curasight A/S Announces Board Changes | CI |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 |
|---|---|---|---|
| Capitalization 1 | 353.1 | 181 | - |
| Enterprise Value (EV) 1 | 333 | 146 | 181 |
| P/E ratio | - | - | - |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | 4.21 x |
| EV / Revenue | - | - | 4.21 x |
| EV / EBITDA | -10.4 x | -2.28 x | -13.9 x |
| EV / FCF | -11.2 x | -2.28 x | - |
| FCF Yield | -8.97% | -43.8% | - |
| Price to Book | - | - | - |
| Nbr of stocks (in thousands) | 19,894 | 19,894 | - |
| Reference price 2 | 17.75 | 9.100 | 9.100 |
| Announcement Date | 2/22/24 | - | - |
1DKK in Million2
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | 43 |
| EBITDA 1 | - | -32.12 | -64 | -13 |
| EBIT 1 | - | -33.21 | -64 | -13 |
| Operating Margin | - | - | - | -30.23% |
| Earnings before Tax (EBT) | -19.49 | - | - | - |
| Net income | -18.35 | - | - | - |
| Net margin | - | - | - | - |
| EPS | - | - | - | - |
| Free Cash Flow 1 | - | -29.86 | -64 | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 2/23/23 | 2/22/24 | - | - |
1DKK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | - | 20.1 | 35 | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | -29.9 | -64 | - |
| ROE (net income / shareholders' equity) | - | -58.8% | -89% | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 2/23/23 | 2/22/24 | - | - |
1DKK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -48.73% | 25.92M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- CURAS Stock
- Financials Curasight A/S
